KING OF PRUSSIA, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ: VERX) (“Vertex” or the “Company”), a leading global provider of indirect tax solutions, today announced financial results for its third quarter ended September 30, 2024. “The third quarter of 2024 was another great quarter for Vertex”, stated David DeStefano, Vertex’s President, Chief Executive Officer and Chairperson of the Board. “Revenue was above the high end of our quarterly guidance, with mid-teens organic revenue growth. We ...

I publish my best ideas and top coverage on the Growth Stock Forum . If you're interested in finding great growth stocks, with a focus on biotech, consider signing up. We focus on attractive risk/reward situations and track each of our portfolio and watchlist stocks closely. To receive e-mail notifications for my public articles and blogs, please click the follow button . And to go deeper, sign up for a free trial to Growth Stock Forum.Shares of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) have appre ...

We expect Vertex Pharmaceuticals Incorporated (VRTX) to surpass expectations when it reports third-quarter 2024 results on Nov. 4, after market close.The Zacks Consensus Estimate for the to-be-reported quarter’s revenues is pegged at $2.68 billion, while the same for earnings is pinned at $4.13 per share.Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.Let's see how things might have shaped up for the quarter to be reported.Factors Shaping VRTX's Upcoming ResultsVertex currently mark ...

文章核心观点 - 该公司的新型非阿片类止痛药物suzetrigine有望成为一款潜在的重磅药物 [1][2][3][4] - suzetrigine在临床试验中表现出与标准止痛药物相当的疗效,且副作用更小,有望在非阿片类止痛药市场占据一席之地 [3][4] - 根据预测,suzetrigine有望在2030年为公司带来约14亿美元的年收入,对公司业绩增长有重要贡献 [5] - 但suzetrigine的上市批准和市场份额并非板上钉钉,还需要进一步研究和开发来充分发挥其价值 [6] 行业分析 - 全球止痛药市场规模巨大,2023年达到约410亿美元,预计到2030年将增长至约610亿美元 [2] - 非阿片类止痛药具有较低成瘾性,且可与阿片类药物联合使用,满足了临床对此类药物的需求 [3][4] 公司分析 - 该公司正在努力拓展业务范围,摆脱传统的囊性纤维化药物领域 [2] - 该公司正在积极推进suzetrigine的研发,已提交上市申请,预计2025年底前获批 [4] - 该公司有多个其他管线产品也有望在未来几年内获批上市,为公司带来更多收入增长 [5]

KING OF PRUSSIA, Pa., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX), a leading global technology provider of indirect tax solutions, today announced that it will release third quarter 2024 financial results before the market opens on Wednesday, November 6, 2024. A conference call to discuss the results will be held at 8:30 a.m. Eastern Time that same day. Those wishing to participate may do so by dialing 1-412-317-6026 approximately ten minutes prior to start time. A listen-only webcast of th ...

文章核心观点 - Vertex公司拥有一个蓬勃发展的管线,并且继续良好执行 [1] - 文章重点分析了Vertex公司3个商业化或即将商业化的产品及其发布动态 [1] 公司概况 - Vertex公司是一家专注于研发治疗性药物的生物制药公司 [1] - Vertex公司拥有一个质量优良、成熟的管线,并有一条通向成功的道路 [1] 产品分析 Trikafta - Trikafta是Vertex公司最新推出的治疗囊性纤维化的三联疗法 [1] - Trikafta的发布动态良好,有望成为Vertex公司的主要收入来源 [1] Symdeko - Symdeko是Vertex公司另一款治疗囊性纤维化的产品 [1] - Symdeko的销售表现良好,有望成为Vertex公司的重要收入来源 [1] Kalydeco - Kalydeco是Vertex公司最早推出的治疗囊性纤维化的产品 [1] - Kalydeco的销售持续稳定,为Vertex公司贡献了可观的收入 [1]

Overview of Vanguard's Recent Transaction On September 30, 2024, Vanguard Group Inc, a prominent investment firm, expanded its portfolio by acquiring an additional 334,189 shares of Vertex. Inc (VERX, Financial), a leading tax technology provider. This transaction increased Vanguard's total holdings in Vertex to 6,721,315 shares, reflecting a significant endorsement of Vertex's market position and business model. The shares were purchased at a price of $38.51, marking a strategic addition to Vanguard's dive ...

Vertex (VERX) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system. Sin ...

Shares of Vertex Energy, Inc. (VTNR) plummeted more than 58% on Wednesday after the producer and marketer of refined products announced a Restructuring Support Agreement (RSA) with lenders andfiled for bankruptcy protection. With full support from its lenders, Vertex Energy has commenced a Chapter 11 case in the United States Bankruptcy Court for the Southern District of Texas to expedite the transactions under the RSA. The decision comes after the company failed in the renewable energy sector. Vertex's Res ...

Daniel Grizelj I believe that Vertex (NASDAQ:VRTX) stock is significantly undervalued because investors are massively underestimating the value of the company's pain treatment, VX-548. In my view, there's a good chance of VX-548 becoming a huge blockbuster. That's because I think there's a great hunger in America for a drug which treats pain more effectively than acetaminophen and NSAIDs and which patients are unlikely to abuse. And according to my calculations, Vertex's shares do not come close to reflecti ...